drugset / Trial / NCT00789633

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

NCT00789633

Phase 3 Completed 353 enrolled AB Science
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to compare the efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine in patients with advanced/metastatic pancreatic cancer.

Timeline

Start
2008-11-25
Primary completion
2011-12-23
Completion
2012-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Masitinib Small molecule 9 mg/kg Oral
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous